Drug Profile
Research programme: ankylosing spondylitis therapeutic - Janssen Research & Development/ University of Queensland
Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Janssen Research & Development; University of Queensland
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ankylosing spondylitis
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for research development in Ankylosing-spondylitis in Australia
- 11 Jun 2015 Janssen Cilag and Uniquest agree to co-promote and co-develop small molecule therapeutics in countries worldwide for Ankylosing spondylitis
- 11 Jun 2015 Early research in Ankylosing spondylitis in Australia (unspecified route)